PCDH17 and acute myeloid leukemia: To test the prognostic relevance of deregulated PCDH17 expression, we investigated the correlation between PCDH17 expression and clinical outcomes in four independent AML cohorts, all cohorts were dichotomized according to the median expression value of PCDH17. In the TCGA AML cohort (n = 173), patients with low PCDH17 expression had significantly reduced OS (P = 0.021, Fig. 4a) and DFS (P = 0.014, Fig. 4b).